This decision analysis is founded on:
1- Comparative Effectiveness Research, Indirect and Mixed Treatment Comparisons (MTC, NMA) : Positioning your innovative technology in the studied therapeutic area;
2- Interactive Health Economics Modeling: Assessing the cost-effectiveness, the cost-utility or the cost-benefit of your innovative health product or technology;
3- Interactive Budget Impact Analysis (IBIA) : Assessing the affordability of your innovative product.
Publication: Maunoury F1,2, Drugeon B3, Boisson M4,5, Marjanovic N3, Couvreur R3,4, Mimoz O3,4,6, Guenezan J3,4,6, on behalf of the CLEAN-3 Study. Cost-effectiveness analysis of bundled innovative devices versus standard approach in the prevention of unscheduled peripheral venous catheters removal due to complications in France. PLoS One. 2022.
1 Statesia, Le Mans, France; 2 University of Le Mans, GAINS, IRA, Le Mans, France; 3 University Hospital of Poitiers, Emergency Department and Pre-Hospital Care, France; 4 University of Poitiers, School of Medicine and Pharmacy, Poitiers, France; 5 University Hospital of Poitiers, Anesthesia, Intensive Care and Peri-Operative Medicine Department, France; 6 INSERM U1070, Pharmacology of anti-infective drugs, Poitiers, France.
Publication: Maunoury F1, Oury A2, Fortin S2, Thomassin L3, Bohbot S3; Explorer Study. Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France. PLoS One. 2021 Jan 22;16(1):e0245652. doi: 10.1371/journal.pone.0245652. PMID: 33481840; PMCID: PMC7822547.
1 Health Economics, Statesia, Le Mans, France. 2 Global Regulatory Affairs & Market Access, URGO Medical, Chenôve, France. 3 Global Medical Affairs, URGO Medical, Paris, France.
Publication: Salah Ghabri PhD1, Aymeric Binard MD2, Yves-Marie Pers MD3, Franck Maunoury PhD4, J. Jaime Caro MD,CM, FRCPC, FACP567. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value in Health DOI: https://doi.org/10.1016/j.jval.2019.12.003. Available online 13 February 2020.
1 Department of Economic and Public Health Evaluation, French National Authority for Health (HAS), Saint-Denis La Plaine, France 2 Department of Rheumatology, CHU de la Cavale-Blanche, Brest, France 3 Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France 4 STATESIA, Le Mans, France 5 McGill University, Montreal, QC, Canada 6 London School of Economics, London, England, UK 7 Evidera, Boston, MA, USA .
Publication: Gordon Goodall1, Mark Lamotte2, Mafalda Ramos2, Franck Maunoury3, Barbora Pejchalova1, Gérard de Pouvourville4 (2019). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients, Journal of Medical Economics, DOI: 10.1080/13696998.2018.1559600.
1 Edwards Lifesciences S.A., Route de l'Etraz 70, 1260 Nyon, Switzerland, 2 IQVIA Corporate village, Davos building, Da Vincilaan 7, 1930 Zaventem, Belgium, 3 STATESIA, 19 Boulevard Marie et Alexandre Oyon, 72100 Le Mans, France, 4 ESSEC Business School, Av. Bernard Hirsch, B.P. 50105, 95021 Cergy Pontoise Cedex, France
